Ubix Therapeutics, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Orum, Vertex Ink Novel Protein-Deg

Further sales growth for the anti-epileptic cenobamate to create stable cash flow and setting a new strategy for the future. These have been the two major tasks facing Donghoon Lee since he became the

Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collabora